You are here

In-Situ Gelling Protein Polymer Intravascular Embolic Agent for Hepatic Carcinoma

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R42CA168123-02A1
Agency Tracking Number: R42CA168123
Amount: $1,495,828.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: 102
Solicitation Number: PA15-270
Timeline
Solicitation Year: 2015
Award Year: 2016
Award Start Date (Proposal Award Date): 2016-09-09
Award End Date (Contract End Date): 2020-08-31
Small Business Information
324 S STATE ST STE 221, Salt Lake City, UT, 84111-5226
DUNS: 828787379
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 HAMID GHANDEHARI
 (801) 587-1566
 hamid.ghandehari@pharm.utah.edu
Business Contact
 DARWIN CHENEY
Phone: (801) 587-1514
Email: dcheney@theratarget.com
Research Institution
 UNIVERSITY OF UTAH
 75 SOUTH 2000 EAST
SALT LAKE CITY, UT, 84112-8930
 Nonprofit college or university
Abstract
SUMMARY This STTR Phase II proposal addresses the significant need for improved treatment options for patients with liver cancerthe fifth highest incidence of cancer in the worldBecause of the lack of symptomshepatocellular carcinomaHCCis detected at advanced stages inof casesfor which theyear survival rate isand atyears it isThe only curative option for advanced HCC is surgical liver resection and liver transplantationunfortunately not available to most patients due to the lack of donor livers and the rapid progression of the diseaseAs HCC is generally unresponsive to systemic chemotherapytranscatheter arterial chemoemobolizationTACEis the most widely usedlocalized treatment that can slow the progression of the diseaseCurrent embolizing agents are deficient in precision of catheter delivery or compatibility for effective delivery of chemotherapeutic agentsespecially high molecular weight biotherapeuticsThe objective of the proposed work is to characterize the novel liquid embolizing agent composed of the genetically engineered protein polymerSELPsilk elastinlike proteinKwhich based on our previous work has demonstrated properties uniquely suited for this applicationUnlike existing agentsSELPK will be injectable as a liquidable to penetrate into the tumor arteriesand transform to an insoluble hydrogel in situ forming a substantially durable occlusionThe embolizing liquid will be completely aqueous and compatible with drugs and new biotherapeuticsenabling their localized controlled releaseThe protein based SELPK will eventually biodegradeenabling subsequent TACE treatmentsSELPK liquid embolic will enable the controlled delivery of chemotherapeutic drugs and new biotherapeutic agents with increased precision of transcatheter delivery for more selective embolizationreduced off target toxicityand reduced collateral damage to the healthy liverConsequentlyTACE treatment will be offered to a larger patient population having a greater number of tumors and or greater tumor sizeThe aims of the research areto characterize the delivery of single and multiple drugs via the SELPK gel networkto conduct in vivo studies in the McA RHHCC liver tumor rat model to evaluate therapeutic performanceto conduct SELPK manufacturing and analytical methods developmentandto conduct GLP preclinical toxicology and performance testing of manufactured SELPK embolic NARRATIVE This STTR Phase II proposal details the rationale and the research plan for the development of a novel liquid embolizing agent composed of the genetically engineered protein polymerSELPsilk elastinlike proteinKfor treatment of hepatocellular carcinoma by transcatheter arterial chemoembolizationTACESELPK embolic will improve the precision of embolizationthe compatibility with newly developed drugsand the selectivity of tumor specific therapyConsequentlyTACE treatment will be offered to a larger patient population having a greater number of tumors and or greater tumor sizefor which few treatment options exist

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government